These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 12220082)
21. Numerical selection of optimal tumor imaging agents with application to engineered antibodies. Williams LE; Wu AM; Yazaki PJ; Liu A; Raubitschek AA; Shively JE; Wong JY Cancer Biother Radiopharm; 2001 Feb; 16(1):25-35. PubMed ID: 11279795 [TBL] [Abstract][Full Text] [Related]
22. A pharmacokinetic model for radioimmunotherapy delivered through cerebrospinal fluid for the treatment of leptomeningeal metastases. Lv Y; Cheung NK; Fu BM J Nucl Med; 2009 Aug; 50(8):1324-31. PubMed ID: 19617331 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. Palm S; Enmon RM; Matei C; Kolbert KS; Xu S; Zanzonico PB; Finn RL; Koutcher JA; Larson SM; Sgouros G J Nucl Med; 2003 Jul; 44(7):1148-55. PubMed ID: 12843231 [TBL] [Abstract][Full Text] [Related]
24. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model. Cao Y; Jusko WJ J Pharmacokinet Pharmacodyn; 2014 Dec; 41(6):571-80. PubMed ID: 25146360 [TBL] [Abstract][Full Text] [Related]
26. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Stroomer JW; Roos JC; Sproll M; Quak JJ; Heider KH; Wilhelm BJ; Castelijns JA; Meyer R; Kwakkelstein MO; Snow GB; Adolf GR; van Dongen GA Clin Cancer Res; 2000 Aug; 6(8):3046-55. PubMed ID: 10955783 [TBL] [Abstract][Full Text] [Related]
27. Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients. Wong JY; Chu DZ; Yamauchi D; Odom-Maryon TL; Williams LE; Liu A; Esteban JM; Wu AM; Primus FJ; Beatty JD; Shively JE; Raubitschek AA J Nucl Med; 1998 Dec; 39(12):2097-104. PubMed ID: 9867150 [TBL] [Abstract][Full Text] [Related]
28. Spatial distribution of tumor-specific monoclonal antibodies in human melanoma xenografts. Shockley TR; Lin K; Nagy JA; Tompkins RG; Yarmush ML; Dvorak HF Cancer Res; 1992 Jan; 52(2):367-76. PubMed ID: 1728408 [TBL] [Abstract][Full Text] [Related]
29. Mechanism of accumulation of 99mTc-sulesomab in inflammation. Skehan SJ; White JF; Evans JW; Parry-Jones DR; Solanki CK; Ballinger JR; Chilvers ER; Peters AM J Nucl Med; 2003 Jan; 44(1):11-8. PubMed ID: 12515870 [TBL] [Abstract][Full Text] [Related]
30. Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. Baxter LT; Jain RK Microvasc Res; 1991 Jan; 41(1):5-23. PubMed ID: 2051954 [TBL] [Abstract][Full Text] [Related]
31. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma. Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754 [TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and radiation dosimetry of 99Tcm-labelled monoclonal antibody B43.13 in ovarian cancer patients. McQuarrie SA; Baum RP; Niesen A; Madiyalakan R; Korz W; Sykes TR; Sykes CJ; Hör G; McEwan AJ; Noujaim AA Nucl Med Commun; 1997 Sep; 18(9):878-86. PubMed ID: 9352556 [TBL] [Abstract][Full Text] [Related]
33. A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio. Sandström K; Haylock AK; Spiegelberg D; Qvarnström F; Wester K; Nestor M Int J Oncol; 2012 May; 40(5):1525-32. PubMed ID: 22307465 [TBL] [Abstract][Full Text] [Related]
34. 131I-labeled monoclonal antibody targeting neuropilin receptor type-2 for tumor SPECT imaging. Chen L; Wang L; Yan J; Ma C; Lu J; Chen G; Chen S; Su F; Wang W; Su X Int J Oncol; 2017 Feb; 50(2):649-659. PubMed ID: 28000859 [TBL] [Abstract][Full Text] [Related]
35. Transport of fluid and macromolecules in tumors. IV. A microscopic model of the perivascular distribution. Baxter LT; Jain RK Microvasc Res; 1991 Mar; 41(2):252-72. PubMed ID: 2051960 [TBL] [Abstract][Full Text] [Related]
36. Targeting strategies for cancer radiotherapy. Buchsbaum DJ; Rogers BE; Khazaeli MB; Mayo MS; Milenic DE; Kashmiri SV; Anderson CJ; Chappell LL; Brechbiel MW; Curiel DT Clin Cancer Res; 1999 Oct; 5(10 Suppl):3048s-3055s. PubMed ID: 10541342 [TBL] [Abstract][Full Text] [Related]
37. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Cai W; Ebrahimnejad A; Chen K; Cao Q; Li ZB; Tice DA; Chen X Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):2024-36. PubMed ID: 17673999 [TBL] [Abstract][Full Text] [Related]
38. Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody. Heiskanen T; Heiskanen T; Kairemo K Curr Pharm Des; 2009; 15(9):988-1007. PubMed ID: 19275663 [TBL] [Abstract][Full Text] [Related]
39. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients. Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605 [TBL] [Abstract][Full Text] [Related]